Literature DB >> 326665

Capsule size of Cryptococcus neoformans: control and relationship to virulence.

M A Dykstra, L Friedman, J W Murphy.   

Abstract

Capsule size of five isolates of Cryptococcus neoformans was controlled by cultivation in media containing varying amounts of sugar. High concentrations of sugar (e.g., 16%) suppressed encapsulation whereas low concentrations (e.g., 1%) allowed maximal encapsulation. Suppression of capsule size was attributed at least in part to the increased osmolarity of the medium because a medium with low sugar concentration but having high osmolarity (by virtue of added sodium chloride) also produced cells having small capsules. The extent of control was more marked with certain of the isolates than with others. Mice were intravenously inoculated with cells of a single isolate cultivated so as to have either small or large capsules, and virulence was measured by comparing death rates. Results indicate that virulence after such an inoculation is a constant characteristic of an isolate and is not affected by size of the capsule of the cells in the inoculum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326665      PMCID: PMC421499          DOI: 10.1128/iai.16.1.129-135.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Isolation of a dry variant from a mucoid strain of Cryptococcus neoformas and preliminary comparative studies.

Authors:  A KASE; J F METZGER
Journal:  J Bacteriol       Date:  1962-04       Impact factor: 3.490

2.  Effect of degree of encapsulation upon virulence of Cryptococcus neoformans.

Authors:  M L LITTMAN; E TSUBURA
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

3.  The isolation of Cryptococcus neoformans from pigeon nests; with remarks on the identification of virulent cryptococci.

Authors:  C J KAO; J SCHWARZ
Journal:  Am J Clin Pathol       Date:  1957-06       Impact factor: 2.493

4.  Capsule synthesis by Cryptococcus neoformans.

Authors:  M L LITTMAN
Journal:  Trans N Y Acad Sci       Date:  1958-05

5.  [Capsular polyoside of a pathogenic fungus Torulopsis neoformans; relation to virulence].

Authors:  E DROUHET; G SEGRETAIN; J P AUBERT
Journal:  Ann Inst Pasteur (Paris)       Date:  1950-12

6.  An evaluation of various environmental factors affecting the propagation of Cryptococcus neoformas.

Authors:  C M Ishaq; G S Bulmer; F G Felton
Journal:  Mycopathol Mycol Appl       Date:  1968-07-12

7.  A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes.

Authors:  K J Kwon-Chung
Journal:  Mycologia       Date:  1976 Jul-Aug       Impact factor: 2.696

8.  Cryptococcus neoformans. II. Phagocytosis by human leukocytes.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

9.  Cryptococcus neoformans. I. Nonencapsulated mutants.

Authors:  G S Bulmer; M D Sans; C M Gunn
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

10.  In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans.

Authors:  T G Mitchell; L Friedman
Journal:  Infect Immun       Date:  1972-04       Impact factor: 3.441

View more
  55 in total

1.  Does the Capsule Interfere with Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Cryptococcus neoformans and Cryptococcus gattii?

Authors:  Danilo Y Thomaz; Rafaella C Grenfell; Monica S M Vidal; Mauro C Giudice; Gilda M B Del Negro; Luiz Juliano; Gil Benard; João N de Almeida Júnior
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

2.  Expression of capsule-associated genes of Cryptococcus neoformans.

Authors:  Ken Okabayashi; Rui Kano; Shinichi Watanabe; Atsuhiko Hasegawa
Journal:  Mycopathologia       Date:  2005-08       Impact factor: 2.574

3.  Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.

Authors:  R Blackstock; J W Murphy
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  G protein-coupled receptor Gpr4 senses amino acids and activates the cAMP-PKA pathway in Cryptococcus neoformans.

Authors:  Chaoyang Xue; Yong-Sun Bahn; Gary M Cox; Joseph Heitman
Journal:  Mol Biol Cell       Date:  2005-11-16       Impact factor: 4.138

5.  The Mouse Inhalation Model of Cryptococcus neoformans Infection Recapitulates Strain Virulence in Humans and Shows that Closely Related Strains Can Possess Differential Virulence.

Authors:  Liliane Mukaremera; Tami R McDonald; Judith N Nielsen; Christopher J Molenaar; Andrew Akampurira; Charlotte Schutz; Kabanda Taseera; Conrad Muzoora; Graeme Meintjes; David B Meya; David R Boulware; Kirsten Nielsen
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

6.  The Cryptococcus neoformans Rim101 transcription factor directly regulates genes required for adaptation to the host.

Authors:  Teresa R O'Meara; Wenjie Xu; Kyla M Selvig; Matthew J O'Meara; Aaron P Mitchell; J Andrew Alspaugh
Journal:  Mol Cell Biol       Date:  2013-12-09       Impact factor: 4.272

7.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

8.  Resistance to challenge and macrophage activity in mice previously vaccinated with formalin-killed Cryptococcus neoformans.

Authors:  D M Anderson; M A Dykstra
Journal:  Mycopathologia       Date:  1984-06-30       Impact factor: 2.574

9.  Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  J M Small; T G Mitchell; R W Wheat
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

10.  Pathogenesis, lethality, and immunizing effect of experimental cutaneous cryptococcosis.

Authors:  M A Dykstra; L Friedman
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.